ACE2 and COVID-19: On the other hand, a recent report suggested that SARS-CoV-2 could exploit IFN-driven gene TMPRSS2 for the upregulation of ACE2 to enhance infection during lung injury.39 Therefore, the side effects of IFN-I should be noted when it is used for the treatment of COVID-19.